Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D07OAD
|
||||
Former ID |
DNCL002383
|
||||
Drug Name |
GO-203-2c
|
||||
Indication | Late-stage solid tumors [ICD9: 140-199, 210-229; ICD10:C00-C75, C7A, C7B, D10-D36, D3A] | Phase 1/2 | [1] | ||
Company |
Genus Oncology
|
||||
Target and Pathway | |||||
Target(s) | Mucin 1 | Target Info | Inhibitor | [2] | |
WikiPathways | Hematopoietic Stem Cell Differentiation | ||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT02204085) A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health. | ||||
REF 2 | Clinical pipeline report, company report or official report of Genus Oncology. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.